Search results for "PARKINSON'S DISEASE"

showing 10 items of 230 documents

Objective assessment of blinking and facial expressions in Parkinson’s disease using a vertical electro-oculogram and facial surface electromyography

2019

Objective: Hypomimia is a common and early symptom of Parkinson's disease (PD), which reduces the ability of PD patients to manifest emotions. Currently, it is visually evaluated by the neurologist during neurological examinations for PD diagnosis, as described in task 3.2 of the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Since such an evaluation is semi-quantitative and affected by inter-variability, this paper aims to measure the physiological parameters related to eye blink and facial expressions extracted from a vertical electro-oculogram (VEOG) and facial surface electromyography (fsEMG) to differentiate PD patients from healthy control subjects (…

Malemedicine.medical_specialtyvertical electro-oculogramParkinson's diseasegenetic structuresPhysiologyParkinson's disease0206 medical engineeringElectro oculogramBiomedical EngineeringBiophysicsHypomimia02 engineering and technologyElectromyographyAudiologyObjective assessment03 medical and health sciences0302 clinical medicineRating scalePhysiology (medical)spontaneous eye blink rateHumansMedicineElectrodesAgedFacial expressionBlinkingmedicine.diagnostic_testElectromyographybusiness.industryParkinson DiseaseSignal Processing Computer-AssistedElectrooculographymedicine.disease020601 biomedical engineeringfacial surface emgFacial ExpressionElectrooculographyROC CurveArea Under CurveCase-Control StudiesFemalemedicine.symptombusiness030217 neurology & neurosurgeryPhysiological Measurement
researchProduct

The contribution of acetylcholine and dopamine to subprocesses of visual working memory--what patients with amnestic mild cognitive impairment and Pa…

2014

Attentional selection, i.e. filtering out of irrelevant sensory input and information storage are two crucial components of working memory (WM). It has been proposed that the two processes are mediated by different neurotransmitters, namely acetylcholine for attentional selection and dopamine for memory storage. However, this hypothesis has been challenged by others, who for example linked a lack in dopamine levels in the brain to filtering deficits. Here we tested the above mentioned hypothesis in two patient cohorts which either served as a proxy for a cholinergic or a dopaminergic deficit. The first group comprised 18 patients with amnestic mild cognitive impairment (aMCI), the second 22…

Malephysiopathology [Cognitive Dysfunction]Parkinson's diseaseCognitive NeuroscienceDopamineModels NeurologicalExperimental and Cognitive Psychologyphysiopathology [Brain]Neuropsychological TestsCohort StudiesBehavioral Neurosciencechemistry.chemical_compoundDopaminemedicineHumansAttentionCognitive Dysfunctionddc:610metabolism [Dopamine]NeurotransmitterAgedWorking memoryDopaminergicBrainCognitionParkinson Diseasephysiopathology [Amnesia]Middle Agedphysiology [Visual Perception]medicine.diseaseAcetylcholineMemory Short-Termchemistryphysiology [Memory Short-Term]physiology [Attention]Visual PerceptionCholinergicFemalephysiopathology [Parkinson Disease]AmnesiaPsychologyNeurosciencemetabolism [Acetylcholine]Acetylcholinemedicine.drugNeuropsychologia
researchProduct

Preoperative imaging findings in patients undergoing transcranial magnetic resonance imaging-guided focused ultrasound thalamotomy

2021

AbstractThe prevalence and impact of imaging findings detected during screening procedures in patients undergoing transcranial MR-guided Focused Ultrasound (tcMRgFUS) thalamotomy for functional neurological disorders has not been assessed yet. This study included 90 patients who fully completed clinical and neuroradiological screenings for tcMRgFUS in a single-center. The presence and location of preoperative imaging findings that could impact the treatment were recorded and classified in three different groups according to their relevance for the eligibility and treatment planning. Furthermore, tcMRgFUS treatments were reviewed to evaluate the number of transducer elements turned off after…

Maletranscranial magnetic resonance; thalamotomy; neurological disordersParkinson's diseasemedicine.medical_treatmentneurological disordersNeuropathic paintranscranial magnetic resonance030218 nuclear medicine & medical imaging0302 clinical medicineThalamusMass ScreeningRadiation treatment planningScreening proceduresAged 80 and overeducation.field_of_studyMultidisciplinarymedicine.diagnostic_testSettore MED/27 - NeurochirurgiaQRSettore MED/37 - NeuroradiologiaDisease ManagementMiddle AgedMagnetic Resonance ImagingSurgery Computer-AssistedMedicineStereotaxic TechniqueSettore MED/26 - NeurologiaFemaleRadiologyAdultmedicine.medical_specialtyEssential TremorScienceClinical Decision-MakingPopulationNeuroimagingArticleFocused ultrasoundMultiple sclerosisYoung Adult03 medical and health sciencesComputed TomographyMedical researchParkinson’s Disease.Preoperative CaremedicineHumansInterventional Magnetic Resonance ImagingIn patientMovement disorderseducationHigh-intensity Focused Ultrasound AblationUltrasonography InterventionalAgedThalamotomybusiness.industryMagnetic resonance imagingthalamotomySettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)Diseases of the nervous systemSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTomography X-Ray ComputedbusinessMR-guided Focused Ultrasound030217 neurology & neurosurgeryNeurosciencePreoperative imaging
researchProduct

Non-Skeletal Activities of Vitamin D: From Physiology to Brain Pathology.

2019

Vitamin D is a secosteroid hormone regulating the expression of almost 900 genes, and it is involved in the regulation of calcium and phosphate metabolism, immune response, and brain development. Low blood vitamin D levels have been reported in patients affected by various diseases. Despite a large amount of literature data, there is uncertainty surrounding the role of vitamin D as a serum biomarker in Alzheimer’s disease (AD) and Parkinson’s disease (PD). Indeed, the lack of internationally recognized 25(OH)D3 reference measurement procedures and standard materials in the past led to unstandardized serum total 25(OH)D3 results among research and clinical care laboratories. Thus…

Medicine (General)Parkinson's diseasePhysiologyvitamin DDiseaseReviewSecosteroidbrain functionchemistry.chemical_compound25(OH)D3R5-920Immune systemAlzheimer DiseaseVitamin D and neurologyMedicineHumansSecosteroidsBrain functionbusiness.industryParkinson DiseaseGeneral Medicinemedicine.diseaseVitamin D Deficiencyimmune system25(OH)D<sub>3</sub>chemistryParkinson’s diseaseBiomarker (medicine)businessAlzheimer’s diseaseBiomarkersHormoneMedicina (Kaunas, Lithuania)
researchProduct

Role of serotonin in central dopamine dysfunction

2010

The interaction between serotonin (5-HT) and dopamine (DA)-containing neurons in the brain is a research topic that has raised the interest of many scientists working in the field of neuroscience since the first demonstration of the presence of monoamine-containing neurons in the mid 1960. The bulk of neuroanatomical data available clearly indicate that DA-containing neurons in the brain receive a prominent innervation from serotonin (5-hydroxytryptamine, 5-HT) originating in the raphe nuclei of the brainstem. Compelling electrophysiological and neurochemical data show that 5-HT can exert complex effects on the activity of midbrain DA neurons mediated by its various receptor subtypes. The m…

Mesocorticolimbic DA systemNigrostriatal DA systemReceptor Serotonin 5-HTParkinson's diseaseBrain microdialysisAntidepressantDopaminergic functionAntidepressantsSettore BIO/09 - Fisiologia5-HT receptorAntipsychoticParkinson diseaseMicrodialysinervous systemSingle cell recordingDrug addictionAntidepressants;Antipsychotics;Dopaminergic function;Drug addiction;5-HT receptors;Mesocorticolimbic DA system;Microdialysis;Nigrostriatal DA system;Parkinson disease;Single cell recordingAntipsychotic drugs
researchProduct

In Vivo Microdialysis in Parkinson’s Research

2009

Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is primarily characterized by the degeneration of dopamine (DA) neurons in the nigrostriatal system, which in turn produces profound neurochemical changes within the basal ganglia, representing the neural substrate for parkinsonian motor symptoms. The pathogenesis of the disease is still not completely understood, but environmental and genetic factors are thought to play important roles. Research into the pathogenesis and the development of new therapeutic intervention strategies that will slow or stop the progression of the disease in human has rapidly advanced by the use of neurotoxins that specifically target DA ne…

MicrodialysisParkinson's diseaseMPTPNigrostriatal pathwayBiologymedicine.diseasechemistry.chemical_compoundmedicine.anatomical_structureNeurochemicalchemistryIn vivoDopamineBasal gangliamedicineNeurosciencemedicine.drug
researchProduct

Kinesiophobia Levels in Patients with Parkinson’s Disease: A Case-Control Investigation

2021

Background: Kinesiophobia can be an obstacle to physical and motor activity in patients with Parkinson’s disease (PD). PD affects patients’ independence in carrying out daily activities. It also impacts a patient’s biopsychosocial well-being. The objective of this study was to analyze the levels and scores of kinesiophobia in PD patients and compare them with healthy volunteers. Methods: We deployed a case-control study and recruited 124 subjects (mean age 69.18 ± 9.12). PD patients were recruited from a center of excellence for Parkinson’s disease (cases n = 62). Control subjects were recruited from the same hospital (control n = 62). Kinesiophobia total scores and categories were self-rep…

Moderate to severemedicine.medical_specialtyMovement disordersActivities of daily livingParkinson's diseaseKinesiophobiaHealth Toxicology and MutagenesisNeurocienciasFisiologiaMedicina Física y RehabilitaciónArticle03 medical and health sciencesMusculoskeletal and neural physiological phenomena0302 clinical medicineSurveys and QuestionnairesmedicineHumansIn patientMotor activityMovement disordersFisioterapiaAgedbusiness.industryPublic Health Environmental and Occupational HealthRParkinson Disease030229 sport sciencesmusculoskeletal and neural physiological phenomenaFearMiddle Agedmedicine.diseaseCase-Control StudiesMann–Whitney U testPhysical therapyParkinson’s diseasemovement disordersMedicineSistema nerviós Malaltiesmedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Death in the substantia nigra: a motor tragedy

2007

It is well known that the death of dopaminergic neurons of the substantia nigra pars compacta (SNc) is the pathological hallmark of Parkinson's disease (PD), the second most common and disabling condition in the expanding elderly population. Nevertheless, the intracellular cascade of events leading to dopamine cell death is still unknown and, consequently, treatment is largely symptomatic rather than preventive. Moreover, the mechanisms whereby nigral dopaminergic neurons may degenerate still remain controversial. Hitherto, several data have shown that the earlier cellular disturbances occurring in dopaminergic neurons include oxidative stress, excitotoxicity, inflammation, mitochondrial dy…

Motor NeuronsParkinson's diseasePars compactaGeneral NeuroscienceModels NeurologicalDopaminergicNeurogenesisParkinson DiseaseSubstantia nigraBiologymedicine.diseaseNeuroprotectionReceptors DopamineAntiparkinson AgentsSubstantia Nigranervous systemDopaminemedicineAnimalsHumansPharmacology (medical)Neurology (clinical)NeuroscienceNeuroinflammationmedicine.drugExpert Review of Neurotherapeutics
researchProduct

Nanoparticulate Systems for Drug Delivery and Targeting to the Central Nervous System

2010

Brain delivery is one of the major challenges for the neuropharmaceutical industry since an alarming increase in brain disease incidence is going on. Despite major advances in neuroscience, many potential therapeutic agents are denied access to the central nervous system (CNS) because of the existence of a physiological low permeable barrier, the blood-brain barrier (BBB). To obtain an improvement of drug CNS performance, sophisticated approaches such as nanoparticulate systems are rapidly developing. Many recent data demonstrate that drugs could be transported successfully into the brain using colloidal systems after i.v. injection by several mechanisms such as endocytosis or P-glycoprotei…

Movement disorders/Parkinson’s diseaseDrug CarriersPolymersSurface PropertiesReviewsBrainAlzheimer's diseaseMultiple sclerosisDrug Delivery SystemsMovement disorders/Parkinson's diseaseSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoLiposomesNeuropsychopharmacology.AnimalsHumansNanoparticlesMultiple sclerosiParticle SizeNeuropsychopharmacologyAlzheimer’s diseaseMicellesCentral Nervous System Agents
researchProduct

Nitric oxide: Implications for the etiology & treatment of central nervous system disorders

2011

Nitric oxide basal ganglia Parkinson's diseaseSettore BIO/09 - Fisiologia
researchProduct